We are committed to developing safe and
effective innovative drugs to combat the
serious threats posed by cancer and
autoimmune diseases
With well-established R&D and commercialization capabilities, InnoCare is dedicated to addressing
the huge unmet medical needs in the field of cancer and autoimmune diseases, by discovering and
developing first-in-class or best-in-class drugs globally.
Dual A+H Listing and
Two Marketed Products
Pipelines in
Clinical Stage
Clinical
Trials
R&D
Staff
Patents and Patent
Applications
Innovative Pipeline
Blood Tumors
Leading Blood Tumor Pipeline
CD19
CD3xCD20
CCR8
BTK
BCL2
E3 Ligase
Autoimmune Diseases
Differentiated Autoimmune Disease Pipeline
Solid Tumors
Competitive Solid Tumor Pipeline
SHP2
CCR8
DDR
pan-FGFR
pan-TRK
Spotlight
InnoCare 2023 Interim Results Snapshot
m
Revenue
b
Cash and Cash Equivalents
m
R&D Expenses
Jasmine Cui, Ph.D.
Co-founder, Chairwoman and CEO, InnoCare
“We are accelerating pipeline development in stage 2.0, with the goal of launching five to six innovative drugs onto the market within three to five years.”
Subscription for Investor
To stay up-to-date with the latest information from InnoCare,
please subscribe to our investor newsletter
and select the categories to receive news and other information by email.